Webb24 dec. 2010 · Abstract. Smac mimetic compounds (SMCs) potentiate TNFα-mediated cancer cell death by targeting the inhibitor of apoptosis (IAP) proteins. In addition to … WebbSM-164 is a cell-permeable Smac mimetic compound. SM-164 binds to XIAP protein containing both the BIR2 and BIR3 domains with an IC50 value of 1.39 nM and functions …
Targeting triple-negative breast cancers with the Smac-mimetic
WebbSmac mimetics, or IAP antagonists, are a class of drugs currently being evaluated as anti-cancer therapeutics. These agents antagonize IAP proteins, including cIAP1/2 and XIAP, … WebbSmac Mimetics for Cancer Treatment The first Smac mimetic compound with eight amino acids was studied in 2000 [46]. Currently, eight Smac mimetics have been developed, and their anti-cancer potency has been evaluated in different preclinical and clinical studies. capital of michigan state usa
Structural basis for bivalent Smac-mimetics recognition in the IAP ...
Webb1 jan. 2005 · A successful structure-based design and synthesis of a class of highly potent conformationally constrained Smac mimetics is described. The most potent compound … WebbOur previous studies demonstrated that the Smac mimetic compound 3 (SMC3) specifically suppresses c-IAP1 and induces TNF-α autocrine to kill cancer cells. … british women\u0027s tennis players